C urrent guidelines on revascularization for unprotected left main coronary artery (ULMCA) disease largely rely on the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score, an angiographic scoring system that assigns integer points based on anatomic considerations and lesion complexity. 1, 2 Historically, both the American College of Cardiology/American Heart Association and European Society of Cardiology cardiovascular practice guidelines have determined that coronary artery bypass grafting (CABG) is the reference treatment standard for ULMCA revascularization, independent of individual anatomic SYNTAX score. As experience and data have evolved, there is currently a gradient of recommendations for percutaneous coronary intervention (PCI) as an alternative to CABG in patients presenting with high surgical risk and low or intermediate SYNTAX scores, with recommendations that slightly differ on the 2 sides of the Atlantic. 1, 2 Both sets of guidelines agree that CABG is the preferred revascularization strategy for patients with a high SYNTAX score (>32), which typically reflects the presence of extensive multivessel disease (downstream from the ULMCA). However, current guidelines do not clearly address a considerable group of patients who may experience positive outcomes with either CABG or PCI. A recent patient-level analysis of SYNTAX and PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease), the 2 pivotal ULMCA revascularization trials conducted during the era of first-generation drug-eluting stents, reached conclusions that are consistent with our current guidelines. However, these conclusions are dated because they do not account for the most recent technical evolution of both PCI and CABG. 3 Two recently published trials, EXCEL (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study), now enter this discussion, presenting data more reflective of current PCI and CABG practice ( Table 1) . 4, 5 EXCEL demonstrates noninferiority of PCI versus CABG with respect to the primary composite end point (all-cause mortality, myocardial infarction [MI], or stroke) at a median of 3 years, while an opposite trend was observed in NOBLE, which showed a higher Kaplan-Meier estimate of the primary composite end point (all-cause mortality, nonprocedural MI, any repeat revascularization, or stroke) with PCI at 5 years. Therefore, the initial comparison of the main results of EXCEL and NOBLE might tempt us to conclude that the findings point in different directions, adding more confusion than clarity to the ULMCA revascularization discussion. However, there are key differences between the trials that are important to highlight, which may explain these disparate findings. In addition to the different duration of follow-up, with longer duration unraveling greater benefits with CABG as shown in prior investigations, 6 differences in the primary end point definition may have also contributed to these findings. In fact, as opposed to EXCEL, NOBLE includes repeat revascularization and does not include periprocedural MI, which inherently favors CABG. Some dissimilarities in baseline, clinical, and procedural characteristics may also account for the observed findings (Table 2 ). However, when looking at components of the end points, EXCEL and NOBLE share some similarities ( Figure) . Overall, mortality rates are numerically higher with PCI in both studies, but cardiovascular death rates are similar. Periprocedural MI is numerically higher in the CABG groups (significantly in EXCEL), while spontaneous MIs are numerically greater in the PCI groups (significantly in NOBLE). Periprocedural complications are more common with CABG in both trials. Stroke is similar in both treatment arms of EXCEL, while it trends toward a higher risk with PCI in NOBLE, which in the absence of plausible alternative explanations probably reflects the play of chance. Not surprisingly, repeat revascularization is greater with PCI in both studies. Interestingly, there are significantly less stent thrombosis with PCI than symptomatic graft occlusion with CABG in EXCEL, while there are no differences in NOBLE likely because of a higher rate of stent thrombosis, which may be attributed to the use of stents with thicker struts. Whether the results of NOBLE would have been different if stents with a similar profile were used such as those used in EXCEL remains speculative.
Perhaps the most notable finding in both EXCEL and NOBLE is the limited usefulness of the SYNTAX score to differentiate the results of PCI versus CABG based on coronary anatomic complexity. In EXCEL, the sites systematically Implications of Evolving Data on Clinical Practice underestimated the SYNTAX score compared with core-lab assessment. This resulted in the inclusion of one third of patients enrolled in the trial having a high SYNTAX score, a group who should have been excluded. Furthermore, the conventional SYNTAX score tertiles did not separate the outcomes of PCI versus CABG. This might be because the high SYNTAX score calculated in patients with ULMCA plus a few additional lesions (ie, because of the large amount of myocardium at jeopardy rather then the number of lesions) is not as predictive as the high SYNTAX score achieved in true multiple complex anatomic multivessel disease. Ironically, the SYNTAX score was initially introduced in response to common statements such as "there is three-vessel disease and... there is three-vessel disease!," but after EXCEL and NOBLE, we now realize that perhaps "there is high SYNTAX score... and there is high SYNTAX score!" (ie, the one involving patients with left main disease and the one involving patients with multivessel disease). Therefore, this leads to question the validity of the current ULMCA guideline revascularization recommendations, which are mainly based on existing SYNTAX score categories. 1, 2 What lessons can we draw from new trial data on ULMCA revascularization, and how might this effect our clinical practice and guidelines? It might be appropriate that after EXCEL and NOBLE, the SYNTAX score-based approach for ULMCA Appreciating the unchanged benefit of CABG, recommendations could become class I for PCI being not only an attractive alternative treatment option for selected patients, but also an option now supported by a stronger level of evidence. New recommendations on ULMCA revascularization should be more patient-centered, based on the earlyand long-term trade-offs of each procedure. These emerging data clearly provide more substance for heart team discussion and facilitate how physicians can more clearly present treatment alternatives to their patients, taking into account patient preferences and characteristics (ie, age) into decision-making. This information will serve to further enable our patients to make well-informed decisions when working with the heart team to achieve their desired clinical outcomes.
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